Memantine: update on the current evidence

No abstract is available for this paper.

• Publication year

  2003

• Venue

  International Journal of Geriatric Psychiatry

• Publication date

  2003-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/GPS.939PMID 12973750
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Resource Utilisation and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer’s Disease

  2012cited by this paper
• Neuroprotective and symptomatological action of memantine relevant for alzheimer’s disease — a unified glutamatergic hypothesis on the mechanism of action

  2009cited by this paper
• Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy

  2003cited by this paper
• Memantine in Vascular Dementia

  2003cited by this paper
• Memantine in moderate-to-severe Alzheimer's disease.

  2003cited by this paper
• A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500)

  2002cited by this paper
• Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia: A Randomized, Placebo-Controlled Trial (MMM 300)

  2002cited by this paper
• The question of familial meningiomas and schwannomas:

  2000cited by this paper
• Incidence of and risk factors for hallucinations and delusions in patients with probable AD

  2000cited by this paper
• Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group.

  2000cited by this paper
• Detailed assessment of cognition and activities of daily living in moderate to severe Alzheimer's disease

  2000cited by this paper
• Pharmacologic Rationale for Memantine in Chronic Cerebral Hypoperfusion, Especially Vascular Dementia

  1999cited by this paper
• Worldwide Prevalence and Incidence of Dementia

  1999cited by this paper
• The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease

  1999cited by this paper
• Pharmacologic rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia.

  1999cited by this paper
• Memantine in severe dementia: results of the 9M‐best study (benefit and efficacy in severly demented patients during treatment with memantine)

  1999cited by this paper
• Challenging the cholinergic hypothesis in Alzheimer disease.

  1999cited by this paper
• Severe dementia: a common condition entailing high costs at individual and societal levels

  1999cited by this paper
• Glutamate in CNS disorders as a target for drug development: an update.

  1998cited by this paper
• Glutamate toxicity in chronic neurodegenerative disease.

  1998cited by this paper
• An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease

  1997cited by this paper
• Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy.

  1997cited by this paper
• Effects of the Uncompetitive NMDA Receptor Antagonist Memantine on Hippocampal Long‐term Potentiation, Short‐term Exploratory Modulation and Spatial Memory in Awake, Freely Moving Rats

  1996cited by this paper
• Infusion of (+) -MK-801 and memantine -- contrasting effects on radial maze learning in rats with entorhinal cortex lesion.

  1996cited by this paper
• Triggering and execution of neuronal death in brain ischaemia: two phases of glutamate release by different mechanisms.

  1994cited by this paper
• Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan).

  1993cited by this paper
• Functional Assessment Staging (FAST) in Alzheimer's Disease: Reliability, Validity, and Ordinality

  1992cited by this paper
• Assessing Alzheimer Severity With a Global Clinical Scale

  1992cited by this paper
• Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study.

  1992cited by this paper
• Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial.

  1991cited by this paper
• Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic?

  1990cited by this paper
• Excitatory amino acids and Alzheimer's disease.

  1989cited by this paper
• Cost benefits of a medically supervised day treatment program for patients with Alzheimer's disease and other forms of dementia

  1989cited by this paper
• Pathological verification of ischemic score in differentiation of dementias

  1980cited by this paper

• Canadian Network for Mood and Anxiety Treatments (CANMAT) and International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) 2025 International Guidelines for the Management of Patients with Obsessive-Compulsive Disorder

  2026cites this paper
• Andrographolide increases adult hippocampal neurogenesis and prolongs contextual fear memory

  2025cites this paper
• Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.

  2025cites this paper
• Bridging the gap between target-based and phenotypic-based drug discovery

  2024cites this paper
• Hydrophilic gold nanospheres: influence of alendronate, memantine, and tobramycin on morphostructural features

  2022cites this paper
• Exploring The Role and Effect of Memantine and its Correspondents for the Treatment of Alzheimer’s Disease

  2021cites this paper
• Assay of Memantine Hydrochloride by UV Spectrophotometer

  2019cites this paper
• A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder.

  2019cites this paper
• Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based Design.

  2016cites this paper
• Biomolecular screening for inhibitors of butyrylcholinesterase : identification and characterization using in vitro and in silico tools

  2013cites this paper
• Cognitive Enhancers (Nootropics). Part 1: Drugs Interacting with Receptors

  2012cites this paper
• Tratamento da demência vascular

  2011cites this paper
• Treatment of vascular dementia. Recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology

  2011cites this paper
• [Memantine in the pharmacologic treatment of moderately severe to severe Alzheimer's disease in Spain (MEMORY study)].

  2010cites this paper
• Prescribing of drugs for Alzheimer's disease: a South African database analysis

  2010cites this paper
• Effect of Memantine on Overactive Detrusor in Rats With Spinal Cord Injury

  2010cites this paper
• Mechanism of block and behavioral effects of the N-methyl-D-aspartate receptor antagonists memantine and ketamine

  2008cites this paper
• Glutamate-glutamine cycling in Alzheimer's disease.

  2007cites this paper
• Memantine produces modest reductions in heroin-induced subjective responses in human research volunteers

  2007cites this paper
• Memantine for Alcohol Dependence: An Open-label Pilot Study

  2007cites this paper
• [Alzheimer Disease].

  2007cites this paper
• The Aβcentric Pathway of Alzheimer’s Disease

  2007cites this paper
• Maladie d’Alzheimer: Mise à jour en 2007

  2007cites this paper
• A retrospective study of memantine in children and adolescents with pervasive developmental disorders

  2007cites this paper
• Neurodegenerative diseases and memory

  2007cites this paper
• Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease.

  2006cites this paper
• Memantine Reduces Hematoma Expansion in Experimental Intracerebral Hemorrhage, Resulting in Functional Improvement

  2006cites this paper
• La Lunga Attesa: Towards a Molecular Approach to Neuroimaging and Therapeutics in Alzheimer's Disease

  2006cites this paper
• Coadministration of Memantine with Acetylcholinesterase Inhibitors

  2006cites this paper
• Added Therapeutic Value of Memantine in the Treatment of Moderate to Severe Alzheimer’s Disease

  2006cites this paper
• Therapeutic strategies for vascular dementia

  2005cites this paper
• An evaluation of the reinforcing effects of memantine in cocaine-dependent humans.

  2005cites this paper
• Memantine does not influence AChE inhibition in rat brain by donepezil or rivastigmine but does with DFP and metrifonate in in vivo studies

  2005cites this paper
• Management of Mild to Moderate Alzheimer Disease

  2004cites this paper
• Memantine

  2004cites this paper
• Management of Mild to Moderate

  2004cites this paper
• Neurodegenerative diseases and oxidative stress

  2004cites this paper
• Current awareness in human psychopharmacology

  2003cites this paper
• Geriatric Psychiatry

  2003cites this paper
• Treatment of Vascular Dementia

  2002cites this paper